alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014184EN.01004101.xml

| 16.6.2014 | EN | Official Journal of the European Union | C 184/41 |
| --- | --- | --- | --- |

16.6.2014

EN

Official Journal of the European Union

C 184/41

---

Action brought on 4 March 2014 — ZZ v Parliament

(Case F-17/14)

2014/C 184/67

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: M. Casado García-Hirschfeld, lawyer)

Applicant:

Defendant: European Parliament

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision not to award the applicant three merit points in the 2012 promotion year.

Form of order sought

Form of order sought

| — | Annul the appointing authority’s decision of 3 July 2013 on determining merit points for 2012; |
| --- | --- |

—

Annul the appointing authority’s decision of 3 July 2013 on determining merit points for 2012;

| — | Annul, so far as is necessary, the decision of 6 December 2013 rejecting the applicant’s complaint; |
| --- | --- |

—

Annul, so far as is necessary, the decision of 6 December 2013 rejecting the applicant’s complaint;

| — | Order the defendant to pay the costs in their entirety. |
| --- | --- |

—

Order the defendant to pay the costs in their entirety.

---
§ 582.1091 Succinic acid. ( a ) *Product.* Succinic acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Exhibit



	
			
	


	 
	 







March 15, 2017


Kathleen Philips
Chief Financial Officer, 
Zillow, Inc.
1301 Second Avenue, Suite 3100
Seattle, WA 98101


Re: Delay of Sublease Commencement Date


Dear Ms. Philips,


I am writing in regards to the Sub-Sublease Agreement dated January 12, 2017 (the “Sub-Sublease Agreement”) between Zillow, Inc. (“Zillow”) and Acucela Inc. (“Acucela”). The purpose of this letter is to document the approval of Zillow to delay the Sublease Commencement Date of the Sub-Sublease Agreement from May 1, 2017, to June 1, 2017 (the “Delay Period”).  During the Delay Period, Acucela acknowledges and agrees that (i) Zillow shall not be liable to Acucela or responsible for the payment of any Rent, Additional Rent, property taxes, operating expenses or any other costs or expenses that may be required or incurred under the Sub-Sublease Agreement and (ii) Acucela shall be and will remain solely liable and responsible for the due keeping, performance, and observance of all of its obligations under the Sublease Agreement (as defined in the Sub-Sublease Agreement), including, without limitation, the payment of any Rent, Additional Rent, property taxes, operating expenses or any other costs or expenses which are incurred or become payable.  


All other terms and conditions of the Sublease Agreement shall remain unchanged and in full force and effect.




Sincerely,
Acucela Inc.


/s/ John Gebhart                                          
By: John Gebhart, Chief Financial Officer




Approved and agreed:


Zillow, Inc.


By: /s/ Kathleen Philips    
Name: Kathleen Philips
Title: Chief Financial Officer, Chief Operating Officer and Treasurer
Date: March 15, 2017
§ 582.5461 Manganese sulfate. ( a ) *Product.* Manganese sulfate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
38687.

#### CARR v. JOHN J. WOODSIDE STORAGE COMPANY, INC., *et al.*

Decided November, 28, 1961.

Jordan, Judge.

The judgment of this court *(Carr v. John J. Woodside Storage Co.,*103 Ga. App. 858, 120 SE2d 907), affirming the trial court’s denial of a new trial to the plaintiff, having been reversed by the Supreme Court of Georgia on certiorari *(Carr v. John J. Woodside Storage Co.,*217 Ga. 438), the said judgment of this court is vacated and the judgment of the trial court denying the motion for new trial is reversed in accordance with the judgment of the Supreme Court.

*Judgment reversed.*

*All the Judges concur.*

*863
      *Randall Evans, Jr.,*for plaintiff in error.

*Robert E. Knox, Fulcher, Fulcher, Hagler & Harper, Gould B. Harper,*contra.
CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                               ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES--OXLEY ACT OF 2002


         In connection with the Quarterly Report of GVC Venture Corp. (the
"Company") on Form 10-QSB for the period ended September 30, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Marc Hanover, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss. 1350, adopted pursuant to Section 906 of the Sarbanes--Oxley Act of
2002 that to my knowledge:

         (1)   The Report fully complies with the requirements of Section 13(a)
               of the Securities Exchange Act of 1934; and

         (2)   The information contained in the Report fairly presents, in all
               material respects, the financial condition and results of
               operations of the Company.



                                                   /s/ Marc Hanover
                                                   -----------------------
                                                   Name Marc Hanover
                                                   Chief Financial Officer


Date: November 8, 2002
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5965 Positive end expiratory pressure breathing attachment. ( a ) *Identification.* A positive end expiratory pressure (PEEP) breathing attachment is a device attached to a ventilator that is used to elevate pressure in a patient's lungs above atmospheric pressure at the end of exhalation.
( b ) *Classification.* Class II (performance standards).
# C_2014142EN.01002801.xml

| 12.5.2014 | EN | Official Journal of the European Union | C 142/28 |
| --- | --- | --- | --- |

12.5.2014

EN

Official Journal of the European Union

C 142/28

---

Request for a preliminary ruling from the Conseil d’État (France) lodged on 6 March 2014 — FCD — Fédération des entreprises du commerce et de la distribution, FMB — Fédération des magasins de bricolage et de l’aménagement de la maison v Ministre de l’écologie, du développement durable et de l’énergie

(Case C-106/14)

2014/C 142/35

Language of the case: French

Referring court

Referring court

Conseil d’État

Parties to the main proceedings

Parties to the main proceedings

Applicants: FCD — Fédération des entreprises du commerce et de la distribution, FMB — Fédération des magasins de bricolage et de l’aménagement de la maison

Applicants:

Defendant: Ministre de l’écologie, du développement durable et de l’énergie

Defendant:

Question referred

Question referred

‘Where an “article” within the meaning of Regulation No 1907/2006 (REACH) (1) is composed of several elements which themselves meet the definition of “article” given by the regulation, are the obligations resulting from Article 7(2) and Article 33 of the regulation to apply only with regard to the assembled article or with regard to each of the elements which meet the definition of “article”?’

1

---

(1)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ 2006 L 396, p. 1)

1

---
Securities and Exchange Commission
                              Washington, DC 20549

                                    Form 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) August 9, 2002
                                                 --------------

                                  ASTRALIS LTD.
             (Exact Name of Registrant as Specified in its Charter)

         Delaware                    000-30997                   84-1508866
--------------------------------------------------------------------------------
(State or Other Jurisdiction       (Commission                 (IRS Employer
    of Incorporation)              File Number)              Identification No.)

75 Passaic Avenue, Fairfield, New Jersey                                 07004
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)                              (Zip Code)

Registrant's telephone number, including area code (973) 227-7168
                                                   --------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


<PAGE>

ITEM 9. REGULATION FD DISCLOSURE.

      On August 9, 2002, Astralis Ltd. (the "Company") submitted to the
Securities and Exchange Commission the certification of the Company's report on
Form 10-QSB for the quarter ended June 30, 2002 by its chief executive officer
and chief financial officer as required pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.


<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                 ASTRALIS LTD.

Date: August 9, 2002                             By: /s/ Mike Ajnsztajn
                                                         ------------------
                                                         Mike Ajnsztajn
                                                         Chief Executive Officer
##### 



Exhibit 31.1 CERTIFICATION REQUIRED BY
RULE 13a-14(a) OR RULE 15d-14(d) AND UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph J. Ueberroth, certify that:  1.
    
    I have reviewed this Annual Report on Form 10-K of Ambassadors
International, Inc.;  2.
    
    Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;  3.
    
    Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this report;  4.
    
    The registrants other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant and have:  (a)
    
    Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;  (b)
    
    Evaluated the effectiveness of the registrants disclosure
controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; and  (c)
    
    Disclosed in this report any change in the registrants
internal control over financial reporting that occurred during the
registrants most recent fiscal quarter (the registrants fourth
fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
registrants internal control over financial reporting; and  5.
    
    The registrants other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrants auditors and the audit committee of the
registrants board of directors (or persons performing the equivalent
functions):  (a)
    
    All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial
information; and  (b)
    
    Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrants
internal control over financial reporting. March 12, 2004 /s/ Joseph J. Ueberroth  
 55
<PAGE>
 
                                                                    EXHIBIT 23.1

                         Consent of Ernst & Young LLP


We consent to the incorporation by reference in the Registration Statement 
(Form, S-8 No. 33-80927) pertaining to the 1993 Stock Option Plan, 1995 Employee
Stock Purchase Plan and the 1995 Non-Employee Director Stock Option Plan of our
report dated April 3, 1997, with respect to the consolidated financial
statements and schedule of Summit Medical Systems, Inc. for the three years
ended December 31, 1996, included in its Annual Report (Form 10-K) filed with
the Securities and Exchange Commission.


                                                       /s/ Ernst & Young LLP

Minneapolis, Minnesota
April 3, 1997
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3450 Gentamicin test system. ( a ) *Identification.* A gentamicin test system is a device intended to measure gentamicin, an antibiotic drug, in human specimens. Measurements obtained by this device are used in the diagnosis and treatment of gentamicin overdose and in monitoring levels of gentamicin to ensure appropriate therapy.
( b ) *Classification.* Class II.
INITIAL REVIEW ENGINEERING REPORT

PMN: 13

- 0810 0811, 0812, 0813, 0814, 0815, 0816, 0817, 0 9, 0820,

0821

Focus Ready Draft 8/29/2013

ENGINEER: Prothero \ REC

SUBMITTER:

USE:_INITIAL REVIEW ENGINEERING REPORT

PMN: 13

- 0810 0811, 0812, 0813, 0814, 0815, 0816, 0817, 08 , 0820,

0821_INITIAL REVIEW ENGINEERING REPORT

PMN: 13

- 0810 0811, 0812, 0813, 0814, 0815, 0816, 0817, 08 , 0820,

0821_ INITIAL REVIEW ENGINEERING REPORT

PMN: 13

- 0810 0811, 0812, 0813, 0814, 0815, 0816, 0817, 08 , 0820,

0821
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.2220 Synthetic cell and tissue culture media and components. ( a ) *Identification.* Synthetic cell and tissue culture media and components are substances that are composed entirely of defined components (e.g., amino acids, vitamins, inorganic salts) that are essential for the survival and development of cell lines of humans and other animals. This does not include tissue culture media for human ex vivo tissue and cell culture processing applications as described in § 876.5885 of this chapter.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60583, Sept. 12, 1980, as amended at 54 FR 25044, June 12, 1989; 66 FR 27024, May 16, 2001; 66 FR 38789, July 25, 2001]
AFS-12-373-E May 31, 2012

Mr. Richard E. Druschel

7437 Pine Vista Drive Brighton, MI 48116

Dear Mr. Druschel:

This letter is in response to your correspondence sent to the public docket dated May 1, 2012 (public docket No. FAA-2003-16009) petitioning the Federal Aviation Administration for an extension to Exemption No. 8125. That exemption from 14 Code of Federal Regulations (CFR) § 91.109(a) and (b)(3) allowed you to conduct flight instruction in certain Beechcraft aircraft equipped with a functioning throwover wheel instead of functioning dual controls.

On August 31, 2011, the FAA amended 14 CFR Part 91 related to throwover control wheels (76 FR 54095). A copy of this rule change is enclosed for your information.

Because the relief you seek is now covered under the new rule, we will take no further action on your petition.

Sincerely,

/s/ Ida Klepper Manager, Airman and Airspace Rules Division
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 16-51446

Summary Calendar

STUART MCMULLEN, 

 Plaintiff - Appellant

v.

DEANNA CAIN, also known as Deanna McMullen Cain, also known as 

Deanna Michelle McMullen, also known as Deanna Michelle Cain, 

 Defendant - Appellee

Appeal from the United States District Court

for the Western District of Texas

USDC No. 1:16-CV-716

Before WIENER, DENNIS, and SOUTHWICK, Circuit Judges.

PER CURIAM:*

Stuart McMullen removed this case from Texas state court to federal 

district court as a purported civil rights case under 28 U.S.C. § 1443(1). The 

district court remanded the case to state court, concluding that it lacked 

subject matter jurisdiction. McMullen appeals. 

 

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5TH 

CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

June 13, 2018

Lyle W. Cayce

Clerk

 Case: 16-51446 Document: 00514511975 Page: 1 Date Filed: 06/13/2018
No. 16-51446

2

The Supreme Court has held that, for removal under § 1443(1) to be 

appropriate, “it must appear that the right allegedly denied the removal 

petitioner arises under a federal law ‘providing for specific civil rights stated 

in terms of racial equality.’” Johnson v. Mississippi, 421 U.S. 213, 219 (1975)

(quoting Georgia v. Rachel, 384 U.S. 780, 792 (1966)). As McMullen concedes, 

his claims in this case do not arise under a federal law pertaining specifically 

to racial equality, yet he asks that we disregard the Supreme Court’s 

construction of § 1443(1) as error. This we cannot do.

AFFIRMED.

 Case: 16-51446 Document: 00514511975 Page: 2 Date Filed: 06/13/2018
<PAGE>   1

                                  EXHIBIT 24.4

                      POWER OF ATTORNEY OF LARRY W. MARTIN


         KNOW ALL MEN BY THESE PRESENTS, that the undersigned, Larry W. Martin,
hereby constitutes and appoints Peter A. Allen or Gordon A. Gardiner his true
and lawful attorney-in-fact and agent, for him and his name, place and stead, in
any and all capacities, to sign the Registration Statement on Form S-3 of Data
Dimensions, Inc., a Delaware corporation, and any amendments or supplements
thereto, and to file this Power of Attorney and the Form S-3, with all exhibits
thereto, and other documents in connection therewith with the Securities and
Exchange Commission and the Nasdaq National Market System, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and
every thing requisite and necessary to be done in and about the premises, as
fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming all that said attorney-in-fact and agent may do or
cause to be done by virtue hereof.

         Dated this 4th day of March, 1999.

Signature:


/s/ Larry W. Martin
------------------------------
Larry W. Martin



                                     III-8
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM THE COMPANY'S
UNAUDITED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000 AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                         152,323,526
<SECURITIES>                                    11,388,473
<RECEIVABLES>                                   23,479,245
<ALLOWANCES>                                       420,795
<INVENTORY>                                              0
<CURRENT-ASSETS>                               189,602,817
<PP&E>                                           2,854,900
<DEPRECIATION>                                   1,663,574
<TOTAL-ASSETS>                                 194,330,693
<CURRENT-LIABILITIES>                          101,062,271
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                           120,631
<OTHER-SE>                                      93,147,791
<TOTAL-LIABILITY-AND-EQUITY>                   194,330,693
<SALES>                                                  0
<TOTAL-REVENUES>                                68,838,345
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                 52,530,210
<INCOME-TAX>                                    22,300,000
<INCOME-CONTINUING>                             30,230,210
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    30,230,210
<EPS-BASIC>                                           2.54
<EPS-DILUTED>                                         2.31



</TABLE>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7525 Heparin assay. ( a ) *Identification.* A heparin assay is a device used to determine the level of the anticoagulant heparin in the patient's circulation. These assays are quantitative clotting time procedures using the effect of heparin on activated coagulation factor X (Stuart factor) or procedures based on the neutralization of heparin by protamine sulfate (a protein that neutralizes heparin).
( b ) *Classification.* Class II (performance standards).
[45 FR 60623, Sept. 12, 1980]